Longmore v. Merrell Dow Pharmaceuticals, Inc.

Decision Date15 May 1990
Docket NumberCiv. No. 84-4071.
PartiesLawrence and Linda LONGMORE, Individually, and as parents and natural guardians of David Ronald Longmore, Plaintiffs, v. MERRELL DOW PHARMACEUTICALS, INC., et al., Defendants.
CourtU.S. District Court — District of Idaho

Barry J. Nace, Bethesda, Md., for plaintiffs.

Jeffery J. Carlson and George Berry, Dixon, Carlson & Campillo, Santa Monica, Cal., for defendants.

MEMORANDUM DECISION

CALLISTER, Senior District Judge.

The Court has before it defendants' motions for summary judgment. The Court has heard oral argument and the motions have been fully briefed. The Court must determine if there are any genuine issues of material fact. See Fed.R.Civ.P. 56(c).

In this product liability action, the plaintiffs claim that their child's birth defects were caused by the mother's use of Bendectin during her pregnancy. She took the drug to combat the nauseous effects of morning sickness. The child, David Ronald Longmore, was born with Poland's Syndrome, a condition that leaves him without a chest muscle on the right side and with a shortening and webbing of his fingers on his right hand. David's mother and father filed this action individually and on behalf of David, claiming that the Bendectin caused David's birth defects.

The defendants have filed motions for summary judgment pointing to more than thirty-five human epidemiological studies finding no causal connection between Bendectin and birth defects. In response, the plaintiffs' experts will criticize these studies and use chemical analysis along with various types of animal studies to conclude that Bendectin could cause birth defects. Resolution of the summary judgment motions appears simple: the battling experts make summary judgment inappropriate. But the matter is complicated by three circuit courts that have found the plaintiffs' causation evidence insufficient as a matter of law in similar Bendectin litigation. Ealy v. Richardson-Merrell, Inc., 897 F.2d 1159 (D.C.Cir.1990); Brock v. Merrell-Dow Pharmaceuticals, Inc., 874 F.2d 307 (5th Cir.) modified 884 F.2d 166 (5th Cir.), reh'g denied, 884 F.2d 167 (en banc), cert. denied ___ U.S. ___, 110 S.Ct. 1511, 108 L.Ed.2d 646 (1990); Lynch v. Merrell-National Laboratories, Inc., 830 F.2d 1190 (1st Cir.).

The Ealy decision is representative and the most recent decision of these three cases. There, the D.C. Circuit, relying on the earlier case of Richardson v. Richardson-Merrell, Inc., 857 F.2d 823 (D.C.Cir.), cert. denied, ___ U.S. ___, 110 S.Ct. 218, 107 L.Ed.2d 171 (1989), held that testimony of the plaintiffs' experts concerning three types of scientific studies was inadmissible under Federal Rule of Evidence 703:

These three types of studies then—chemical, in vitro test tube, and in vivo animal—cannot furnish a sufficient foundation for a conclusion that Bendectin caused the birth defects at issue in this case. Studies of this kind, singly or in combination, are not capable of proving causation in human beings in the face of the overwhelming body of contradictory epidemiological evidence. Perhaps mindful of this, the last type of evidence considered by Dr. Done consisted of the epidemiological studies. When such studies are available and relevant, and particularly when they are numerous and span a significant period of time, they assume a very important role in determinations of questions of causation.

897 F.2d at 1161 (emphasis added) (quoting from Richardson v. Richardson-Merrell, Inc., supra at 830).

The Ealy court then went on to hold that therefore, under Rule 703, an opinion refuting this scientific consensus the epidemiological studies is inadmissible for lack of an adequate foundation, in the absence of other substantial probative evidence on which to base this opinion. It is this uncontroversial rule of evidence that is that ratio decidendi of Richardson and this case.

In the other two cases cited above, Lynch and Brock, the First and Fifth Circuits reached similar decisions. No Ninth Circuit case has yet come down addressing these issues. The Court is therefore faced with persuasive but not binding precedent. The three circuit decisions placed considerable emphasis on the epidemiological evidence, and the Court will begin its inquiry there.

For obvious reasons, scientists do not investigate the potential toxic effects of a drug by performing tests on human beings. Instead, scientific investigators must use an indirect route and extrapolate their results. Animal studies, epidemiology, chemical analysis, clinical studies, and other analytical tools are all part of the investigative process. The three circuit decisions were particularly impressed with epidemiology which is the statistical study of disease in human populations. Dore, A Commentary on the Use of Epidemiological Evidence in Demonstrating Cause-In-Fact, 7 Harv.Envtl.L.Rev. 429 (1983). By studying large groups of people, epidemiologists can determine the association between exposure to a chemical and disease. For example, epidemiological studies have concluded that exposure to vinyl chloride in the workplace is associated with an increased incidence of cancer in rubber workers. Hall & Silbergeld, Reappraising Epidemiology: A Response to Mr. Dore, 7 Harv.Envtl.L.Rev. 441 (1983). As another example, prenatal exposure to seed treated with methyl mercury is associated with birth defects in children. Id.

As these examples show, epidemiological studies "are general in that they deal with sources of diseases and groups of people rather than particular individuals." Dore, supra at 436. In the context of a civil trial, epidemiological studies could be used to show that a defendant's conduct increased the plaintiff's risk of injury but "could not answer the critical question whether the defendant's conduct actually injured the plaintiff." Dore, supra at 436.

It is also important that an epidemiological association usually requires a 95% level of confidence.1 To explain this using a hypothetical example, assume an epidemiologist observed an increased incidence of Poland's Syndrome among babies born to mothers who had ingested Bendectin during pregnancy. Using a 95% confidence level, the epidemiologist will conclude that ingestion of Bendectin during pregnancy is associated with an increased incidence of Poland's Syndrome only where the probability is one in twenty—or less—that the observation of association resulted from random chance. If the probability is one in nineteen that the events occurred by chance, the association will be deemed "statistically insignificant." Thus, an epidemiologist would find the correlation between Poland's Syndrome and Bendectin ingestion "insignificant" even though the probability is 94.73% (eighteen out of nineteen) that the observed relationship is not related to random chance. It is therefore apparent that the scientific standard for determining causation is much stricter than the standard employed in this Court. While the epidemiologist may conclude that the observed association is insignificant, the "certainty that the observed increase is related to its hypothetical cause rather than mere chance is still far more likely than not." Allen v. United States, 588 F.Supp. 247 (D.Utah 1984), rev'd on other grounds 816 F.2d 1417 (10th Cir.1987). As the Eleventh Circuit has recognized, "a distinction exists between legal sufficiency and scientific certainty." Wells v. Ortho Pharmaceutical Corp., 788 F.2d 741, 745 (11th Cir.1986). That distinction is vitally important in this case, as the following discussion will show.

The standard for determining causation in this Court is drawn from Idaho law. See Erie Railroad Co. v. Tompkins, 304 U.S. 64, 58 S.Ct. 817, 82 L.Ed. 1188 (1938). In Idaho, proximate cause is a factual question normally reserved for the jury. Stephens v. Stearns, 106 Idaho 249, 678 P.2d 41 (1984). With regard to the factual question of causation, the plaintiff need only prove that it is more probably true than not that the mother's ingestion of Bendectin caused David's Poland's Syndrome. Earl v. Cryovac, A Div. of W.R. Grace, 115 Idaho 1087, 772 P.2d 725 (Idaho Ct.App. 1989); Idaho Standard Jury Instruction No. 112. This certainly does not require a confidence level of 95%, 90% or even 80%. A cause-and-effect relationship may be deemed insignificant under stringent scientific standards, but nevertheless establish causation under legal standards. This very point has been considered by the Idaho courts:

Accordingly, when the courts apply medical and scientific evidence to a question of causation, they must interpret the evidence carefully in light of the applicable standard. They may not assume that a causal relationship is probable merely because a physician deems it significant in his diagnosis and treatment of a patient's condition. Neither may they assume that a causal relationship is improbable merely because it has not been documented in a body of research literature where a high degree of certainty is demanded.

Earl v. Cryovac, A Div. of W.R. Grace, supra at 1089-1090, 772 P.2d at 727-728 (emphasis added).

This Court does not mean to imply that epidemiological studies are without worth in proving causation. Certainly they play an important role. Hall & Silbergeld, supra. A jury might find the studies conclusive. But this Court cannot—at this stage of the case—find the epidemiological evidence "overwhelming." The studies are not designed to definitively prove individual causation, and they could label a cause "insignificant" that the legal system would find...

To continue reading

Request your trial
4 cases
  • Merrell Dow Pharmaceuticals, Inc. v. Havner
    • United States
    • Supreme Court of Texas
    • November 13, 1997
    ...courts have denied summary judgment for Merrell Dow on the basis that the evidence raised a fact question. Longmore v. Merrell Dow Pharms., Inc., 737 F.Supp. 1117 (D.Idaho 1990); In re Bendectin Prods. Liab. Litig., 732 F.Supp. 744 (E.D.Mich.1990); Hagen v. Richardson-Merrell, Inc., 697 F.S......
  • Rubanick v. Witco Chemical Corp.
    • United States
    • United States State Supreme Court (New Jersey)
    • August 1, 1991
    ...that benzene caused decedent's leukemia; whether to credit the testimony is for the jury to decide); Longmore v. Merrell Dow Pharmaceutical, 737 F.Supp. 1117, 1118-21 (D.Idaho 1990) (plaintiffs' experts could testify that Bendectin caused birth defects despite defendant's presentation of th......
  • Turpin v. Merrell Dow Pharmaceuticals, Inc.
    • United States
    • United States Courts of Appeals. United States Court of Appeals (6th Circuit)
    • March 11, 1992
    ...of an expert witness's epidemiological opinion of causation under Federal Rule of Evidence 702. See also Longmore v. Merrell-Dow Pharmaceuticals, Inc., 737 F.Supp. 1117 (D.Idaho 1990) (expressly declining to adopt Richardson, Lynch, and Brock approaches); In re Bendectin Products Liability ......
  • NATIONAL CONSUMER CO-OP. BANK v. Madden, Civ. No. 89-00045 DAE.
    • United States
    • U.S. District Court — District of Hawaii
    • May 22, 1990
    ......4 ("Kano") and OFA/California Cooperative, Inc. 5 ("Calif. Co-op"). 6 At that time defendant Jack L. Ayers, Jr. ......
8 books & journal articles
  • Commonly Used Experts
    • United States
    • James Publishing Practical Law Books Archive Qualifying & Attacking Expert Witnesses - 2016 Contents
    • August 4, 2016
    ...with the models used by the expert. Inaccurate data might have been used. Case Longmore v. Merrell Dow Pharmaceuticals, Inc., 737 F. Supp. 1117 (D. Idaho 1990) was an action against a drug manufacturer in which it was alleged that ingestion of the defendant’s drug during pregnancy resulted ......
  • Table of Cases
    • United States
    • James Publishing Practical Law Books Archive Qualifying & Attacking Expert Witnesses - 2015 Contents
    • August 4, 2015
    ...Longman v. Allstate Ins. Co ., 635 So. 2d 343, 353-355 (La. Ct. App. 1994), §551.2.4 Longmore v. Merrell Dow Pharmaceuticals, Inc., 737 F. Supp. 1117 (D. Idaho 1990), §560.5.5 Lopez v. Allstate Insurance. Co., 282 F. Supp. 2d 1095, 1104-1105 (D. Ariz. 2003), §582 Lopez v. Daimler-Chrysler (......
  • Commonly Used Experts
    • United States
    • James Publishing Practical Law Books Archive Qualifying & Attacking Expert Witnesses - 2019 Contents
    • August 4, 2019
    ...with the models used by the expert. Inaccurate data might have been used. CASE Longmore v. Merrell Dow Pharmaceuticals, Inc., 737 F. Supp. 1117 (D. Idaho 1990) was an action against a drug manufacturer in which it was alleged that ingestion of the defendant’s drug during pregnancy resulted ......
  • Table of Cases
    • United States
    • James Publishing Practical Law Books Archive Qualifying & Attacking Expert Witnesses - 2016 Contents
    • August 4, 2016
    ...Longman v. Allstate Ins. Co ., 635 So. 2d 343, 353-355 (La. Ct. App. 1994), §551.2.4 Longmore v. Merrell Dow Pharmaceuticals, Inc., 737 F. Supp. 1117 (D. Idaho 1990), §560.5.5 Lopez v. Allstate Insurance. Co., 282 F. Supp. 2d 1095, 1104-1105 (D. Ariz. 2003), §582 Lopez v. Daimler-Chrysler (......
  • Request a trial to view additional results

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT